TC-5619: Completed Phase II enrollment

Targacept completed enrollment of about 200 patients in a double-blind, placebo-controlled, U.S. and Indian Phase II trial to evaluate 1, 5 and 25 mg oral TC-5619. AstraZeneca has an option to license...